Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365157 · ClinicalTrials.gov registry record · Phase 1
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase 1 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 20
- Study locations
NCT00365157 is a Phase 1 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 132 participants, roughly in line with the 126-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target. The trial reports 20 study locations across 3 states.
The verdict
NCT00365157, a Phase 1 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body (metastatic)and kidney dysfunction. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Eribulin Mesylate
Study Locations (20)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Decatur Memorial Hospital - Decatur
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Ingalls Memorial Hospital - Harvey
- Duly Health and Care Joliet - Joliet
- Loyola University Medical Center - Maywood
- Illinois CancerCare-Peoria - Peoria
- Central Illinois Hematology Oncology Center - Springfield
- Southern Illinois University School of Medicine - Springfield
California
- Tower Cancer Research Foundation - Beverly Hills
- City of Hope Comprehensive Cancer Center - Duarte
- City of Hope Antelope Valley - Lancaster
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Contra Costa Regional Medical Center - Martinez
- Veterans Administration Hospital - Martinez - Martinez
- University of California Davis Comprehensive Cancer Center - Sacramento
- City of Hope South Pasadena - South Pasadena
Indiana
- Fort Wayne Medical Oncology and Hematology Inc-Parkview - Fort Wayne
- Community Howard Regional Health - Kokomo
- Northern Indiana Cancer Research Consortium - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2006-10-23 |
| Est. Completion | 2026-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365157
The ClinicalTrials.gov registry entry for NCT00365157 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 126-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Metastatic Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00365157 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Illinois, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT00365157 about?
NCT00365157 is a clinical study titled "Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction". This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body (metastatic)and kidney dysfunction. Drugs used in chemotherapy, such as eri...
What is the current status of trial NCT00365157?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2006-10-23. Estimated completion is 2026-07-09.
What conditions does trial NCT00365157 study?
This clinical trial studies the following conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7.
What interventions are being tested in trial NCT00365157?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT00365157?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00365157 being conducted?
This trial has 20 study locations across California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
RECRUITING · Phase 1
-
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
RECRUITING · Phase 1
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
-
A Study of NX-1607 in Adults With Advanced Malignancies
RECRUITING · Phase 1
-
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Urothelial Carcinoma
All registered trials for this condition
Locally Advanced Urothelial Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.